|
Laboratory outcome measures during randomised treatment phase presented as average [mean (SE)] changes from baseline during weeks 0 – 24 as measured by AUCMB |
|||
| Placebo |
Active |
p |
|
|
|
|||
| HTLV-I proviral loada (log10 copies/105 PBMCs) |
+0.03 (0.10) |
+0.05 (0.13) |
0.92 |
| Total Lymphocytesb (106/L) |
+148.2 (58.0) |
-159.3 (146.7) |
0.07 |
| CD3 Lymphocytesb (106/L) |
+98.4 (63.4) |
-23.2 (151.3) |
0.47 |
| CD3b % |
+0.2 (2.8) |
+4.3 (2.6) |
0.14 |
| CD4b Lymphocytes (106/L) |
+32.6 (33.1) |
+10.4 (98.7) |
0.55 |
| CD4b % |
-1.2 (0.9) |
+4.7 (1.8) |
0.01 |
| CD8b Lymphocytes (106/L) |
+65.8 (31.3) |
-38.1 (60.7) |
0.15 |
| CD8b % |
+1.4 (1.2) |
+1.4 (1.9) |
0.99 |
| CD25a % |
-0.8 (1.8) |
+0.3 (0.8) |
0.58 |
| CD69a % |
+0.4 (1.3) |
+1.2 (1.8) |
0.73 |
| CD71a% |
-0.3 (1.0) |
-0.2 (1.9) |
0.97 |
| HLA-DR% |
-4.85 (4.0) |
+3.59 (2.4) |
0.42 |
|
a Data only available on n = 6 in placebo group and n = 7 in active group due to missing baseline data b Data only available on n = 7 in placebo group and n = 7 in active group due to missing baseline data | |||
Taylor et al. Retrovirology 2006 3:63 doi:10.1186/1742-4690-3-63 |
|||